Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells.
Chen H, Cong X, Wu C, Wu X, Wang J, Mao K, Li J, Zhu G, Liu F, Meng X, Song J, Sun X, Wang X, Liu S, Zhang S, Yang X, Song Y, Yang YG, Sun T.
Chen H, et al. Among authors: li j.
Sci Adv. 2020 Jan 29;6(5):eaax4690. doi: 10.1126/sciadv.aax4690. eCollection 2020 Jan.
Sci Adv. 2020.
PMID: 32064335
Free PMC article.